ArticleFrontiers in oncology2025
Integrative single-cell atlas unveils heterogeneity and prognostic value of cancer-associated fibroblasts in gastric cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrating multiple omics and machine learning to reveal the prognostic value of endoplasmic reticulum stress geneTranslational cancer research · 2026Article
- Multi-omics exploration of hypoxia in gastric cancer.World journal of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) exhibits molecular heterogeneity and diverse immune cell infiltration patterns closely associated with patient prognosis. However, a comprehensive understanding of the variations in immune cell phenotypes among different patient subgroups still needs to be improved. In this study, we performed a detailed analysis of the tumor microenvironment in GC by integrating 200,466 single cells from 72 patients across six datasets. We classified patients into immune-deserted, B, T, and myeloid cell subtypes. Using genomic and clinical data from TCGA samples, we identified cellular components associated with tumor histology and genotypes. GC patients were stratified into immune-deserted, B cell, T cell, and myeloid cell subtypes, and we described the pathway and transcription factor activity characteristics of different microenvironment subtypes. Integration of bulk RNA-seq data reveals that fibroblasts and endothelial cells were associated with adverse patient outcomes whereas NK and T cells were notably correlated with improved prognosis. Subsequently, we focused on characterizing cancer-associated fibroblasts (CAFs) and discovered that they acquire new functional properties within the tissue microenvironment, providing evidence of CAF plasticity. We constructed a novel four-gene CAF signature including SPARC, EFEMP1, RGS5 and SERPINE1 which may enhance patient stratification and prognostic prediction of GC patients. qPCR analysis revealed that the significant expressions of SPARC, EFEMP1, RGS5 and SERPINE1 were significantly upregulated in gastric cancer tissues compared to the normal tissues. Our study provides insights into the composition of the tumor microenvironment and construction of a four-gene CAF signature associated with clinical prognosis, offering new perspectives for the clinical management of gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.